Form 4: Apyx Medical Corp COO Granted Stock Options

Shawn David Roman, Chief Operating Officer of Apyx Medical Corp, was granted stock options for 100,000 shares on January 15, 2025.

Summary

• Shawn David Roman, the Chief Operating Officer of Apyx Medical Corp, filed a Form 4 on January 17, 2025, reporting a transaction.
• On January 15, 2025, Roman was granted stock options to purchase 100,000 shares of Apyx Medical Corp common stock at an exercise price of $1.42 per share.
• The options vest ratably over 36 months and will be fully vested and exercisable on January 15, 2028.
• Following the transaction, Roman directly owns options for 100,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates confidence in the company's future, but doesn't provide specific financial details to significantly impact sentiment.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve company performance.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry.
• The vesting schedule of 36 months is typical for such grants.
• Comparing the size of this grant to those of other COOs in similarly sized medical device companies would provide further context.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.

Key Dates